JP7079551B2 - ヒドロキシチロソールおよびボスウェリン酸を有する組成物 - Google Patents

ヒドロキシチロソールおよびボスウェリン酸を有する組成物 Download PDF

Info

Publication number
JP7079551B2
JP7079551B2 JP2019516976A JP2019516976A JP7079551B2 JP 7079551 B2 JP7079551 B2 JP 7079551B2 JP 2019516976 A JP2019516976 A JP 2019516976A JP 2019516976 A JP2019516976 A JP 2019516976A JP 7079551 B2 JP7079551 B2 JP 7079551B2
Authority
JP
Japan
Prior art keywords
hydroxytyrosol
composition
keto
acetyl
boswellic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019516976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529482A (ja
JP2019529482A5 (enExample
Inventor
ヘンダーソン，トッド
グリフィン，デイヴィッド
Original Assignee
ニュートラマックス ラボラトリーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニュートラマックス ラボラトリーズ，インコーポレイテッド filed Critical ニュートラマックス ラボラトリーズ，インコーポレイテッド
Publication of JP2019529482A publication Critical patent/JP2019529482A/ja
Publication of JP2019529482A5 publication Critical patent/JP2019529482A5/ja
Priority to JP2022082301A priority Critical patent/JP7341596B2/ja
Application granted granted Critical
Publication of JP7079551B2 publication Critical patent/JP7079551B2/ja
Priority to JP2023137408A priority patent/JP7562225B2/ja
Priority to JP2024163552A priority patent/JP7876938B2/ja
Priority to JP2026095727A priority patent/JP2026127783A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
JP2019516976A 2016-10-04 2017-04-21 ヒドロキシチロソールおよびボスウェリン酸を有する組成物 Active JP7079551B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022082301A JP7341596B2 (ja) 2016-10-04 2022-05-19 炎症メディエーターのレベルを低減するための組成物及び方法
JP2023137408A JP7562225B2 (ja) 2016-10-04 2023-08-25 炎症メディエーターのレベルを低減するための組成物及び方法
JP2024163552A JP7876938B2 (ja) 2016-10-04 2024-09-20 炎症メディエーターのレベルを低減するための組成物及び方法
JP2026095727A JP2026127783A (ja) 2016-10-04 2026-06-08 炎症メディエーターのレベルを低減するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403807P 2016-10-04 2016-10-04
US62/403,807 2016-10-04
PCT/US2017/028857 WO2018067200A1 (en) 2016-10-04 2017-04-21 Compositions comprising hydroxytyrosol and boswellic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022082301A Division JP7341596B2 (ja) 2016-10-04 2022-05-19 炎症メディエーターのレベルを低減するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019529482A JP2019529482A (ja) 2019-10-17
JP2019529482A5 JP2019529482A5 (enExample) 2020-05-28
JP7079551B2 true JP7079551B2 (ja) 2022-06-02

Family

ID=58664857

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019516976A Active JP7079551B2 (ja) 2016-10-04 2017-04-21 ヒドロキシチロソールおよびボスウェリン酸を有する組成物
JP2022082301A Active JP7341596B2 (ja) 2016-10-04 2022-05-19 炎症メディエーターのレベルを低減するための組成物及び方法
JP2023137408A Active JP7562225B2 (ja) 2016-10-04 2023-08-25 炎症メディエーターのレベルを低減するための組成物及び方法
JP2024163552A Active JP7876938B2 (ja) 2016-10-04 2024-09-20 炎症メディエーターのレベルを低減するための組成物及び方法
JP2026095727A Pending JP2026127783A (ja) 2016-10-04 2026-06-08 炎症メディエーターのレベルを低減するための組成物及び方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022082301A Active JP7341596B2 (ja) 2016-10-04 2022-05-19 炎症メディエーターのレベルを低減するための組成物及び方法
JP2023137408A Active JP7562225B2 (ja) 2016-10-04 2023-08-25 炎症メディエーターのレベルを低減するための組成物及び方法
JP2024163552A Active JP7876938B2 (ja) 2016-10-04 2024-09-20 炎症メディエーターのレベルを低減するための組成物及び方法
JP2026095727A Pending JP2026127783A (ja) 2016-10-04 2026-06-08 炎症メディエーターのレベルを低減するための組成物及び方法

Country Status (9)

Country Link
US (5) US10342802B2 (enExample)
EP (2) EP4623994A3 (enExample)
JP (5) JP7079551B2 (enExample)
CN (2) CN120241745A (enExample)
AU (3) AU2017340126B2 (enExample)
CA (1) CA3039233A1 (enExample)
ES (1) ES3040765T3 (enExample)
PL (1) PL3522874T3 (enExample)
WO (1) WO2018067200A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039233A1 (en) 2016-10-04 2018-04-12 Nutramax Laboratories, Inc. Compositions comprising hydroxytyrosol and boswellic acid
CN115282154A (zh) * 2022-08-15 2022-11-04 武汉科前生物股份有限公司 11-羰基-β-乙酰乳香酸在制备治疗猫传腹药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102451428A (zh) 2010-10-14 2012-05-16 中国中医科学院广安门医院 可用于治疗类风湿关节炎的中药组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358542B2 (en) 1999-12-20 2002-03-19 Usana, Inc. Antioxidant compositions extracted from olives and olive by-products
US7713569B2 (en) 2000-09-01 2010-05-11 Creagri, Inc. Hydroxytyrosol-rich composition from olive vegetation water and method of use thereof
JP3820218B2 (ja) 2000-09-01 2006-09-13 クレアグリ， インコーポレイテッド 植物水からヒドロキシチロソール富化組成物を得る方法
WO2003068171A2 (en) 2002-02-13 2003-08-21 Creagri, Inc. Method and composition for treatment of inflammation and aids-associated neurological disorders
WO2003077860A2 (en) * 2002-03-13 2003-09-25 Biophysica, Inc. BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
EP1582512A1 (en) 2004-03-31 2005-10-05 Cognis IP Management GmbH Process for obtaining hydroxytyrosol from olive leaves extracts
US7625947B2 (en) 2004-06-18 2009-12-01 Laila Nutraceuticals Analogs of 3-O-acetyl-11-keto-β-boswellic acid
JP2008509224A (ja) * 2004-08-09 2008-03-27 クレアグリ， インコーポレイテッド 炎症状態を治療するためのオリーブ組成物及び方法
CN101516364B (zh) * 2006-07-14 2011-12-28 帝斯曼知识产权资产管理有限公司 组合物及其用于治疗、共治疗或预防炎性病症的用途
WO2008006582A1 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
JP2008120716A (ja) 2006-11-10 2008-05-29 Eisai Food Chemical Kk 抗炎症剤
WO2010029578A2 (en) 2008-09-15 2010-03-18 Ganga Raju Gokaraju Synergistic anti-inflammatory compositions comprising boswellia serrata extracts
US9144555B2 (en) * 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
CA3039233A1 (en) 2016-10-04 2018-04-12 Nutramax Laboratories, Inc. Compositions comprising hydroxytyrosol and boswellic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102451428A (zh) 2010-10-14 2012-05-16 中国中医科学院广安门医院 可用于治疗类风湿关节炎的中药组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cancer Res.，2009年，Vol.69,No.14，pp.5893-5900
Current Cancer Drug Targets，Vol.13，2013年，pp.625-639
Journal of Nutritional Biochemistry，Vol.26，2015年，pp.360-368
Molecules，2013年，Vol.18，pp.5265-5287

Also Published As

Publication number Publication date
EP4623994A2 (en) 2025-10-01
JP2026127783A (ja) 2026-08-06
JP7876938B2 (ja) 2026-06-22
CN120241745A (zh) 2025-07-04
JP2022110125A (ja) 2022-07-28
JP7341596B2 (ja) 2023-09-11
PL3522874T3 (pl) 2025-10-06
EP4623994A3 (en) 2025-11-19
CA3039233A1 (en) 2018-04-12
JP7562225B2 (ja) 2024-10-07
WO2018067200A1 (en) 2018-04-12
JP2024166415A (ja) 2024-11-28
AU2017340126B2 (en) 2023-03-02
US10722524B2 (en) 2020-07-28
US20240285648A1 (en) 2024-08-29
JP2019529482A (ja) 2019-10-17
US10342802B2 (en) 2019-07-09
US20200222424A1 (en) 2020-07-16
US11980624B2 (en) 2024-05-14
EP3522874A1 (en) 2019-08-14
US11241444B2 (en) 2022-02-08
ES3040765T3 (en) 2025-11-04
AU2025202875B2 (en) 2026-07-09
US20220110946A1 (en) 2022-04-14
AU2017340126A1 (en) 2019-04-11
AU2023203427B2 (en) 2025-02-06
AU2023203427A1 (en) 2023-06-29
US20180092928A1 (en) 2018-04-05
CN109789110A (zh) 2019-05-21
AU2025202875A1 (en) 2025-05-15
JP2023159387A (ja) 2023-10-31
EP3522874B1 (en) 2025-07-02
US20190231796A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
Jerosch Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient partners especially Omega‐3 fatty acids
JP2024166415A (ja) 炎症メディエーターのレベルを低減するための組成物及び方法
US20250152554A1 (en) Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
KR20040054738A (ko) 시클로옥시게나제-2의 발현 및/또는 활성의 상승 억제를나타내는 쿠르쿠미노이드 조성물
Zhou et al. Role of histone deacetylase inhibitors in non-neoplastic diseases
Song et al. Therapeutic applications of type 2 diabetes mellitus drug metformin in patients with osteoarthritis
TWI454271B (zh) 一種用於治療骨關節炎的草藥組合物
US20200384052A1 (en) Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
Schell A promising natural therapy for equine osteoarthritis
HK1196949A (en) Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
NZ618389B2 (en) Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220519

R150 Certificate of patent or registration of utility model

Ref document number: 7079551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250